Fragile X Screening in Autism: Recommendations
All males with unexplained autism should be routinely tested for Fragile X syndrome as a first-tier genetic test, while females with autism should only be tested when specific clinical indicators are present. 1
Screening Algorithm
Males with Autism
- Routine testing recommended for all males with autism spectrum disorder (ASD) without another identified etiology 1
- This is a first-tier test alongside chromosomal microarray analysis 1
- Expected diagnostic yield: 0.5-5% depending on the population studied 1
Females with Autism
Selective testing only - routine screening does NOT meet evidence-based criteria 1
Test females when ANY of these clinical indicators are present:
- Phenotype compatible with Fragile X (dysmorphic features, intellectual disability)
- Family history positive for X-linked neurodevelopmental disorders
- Family history of premature ovarian insufficiency, ataxia, or tremors in close relatives 1
Important Nuances
Why the Sex Difference?
The literature review identified zero female patients with abnormal Fragile X results from unselected ASD cohorts, making routine screening in females not cost-effective 1. However, case reports demonstrate that females with full mutations can present with high-functioning ASD without intellectual disability 2, so targeted testing based on clinical features remains important.
Declining Yield Over Time
Earlier studies showed 5.3-8% positive rates in males with ASD 1, while recent surveys show only 0.5% (6 of 1,215 children) 1. This decline likely reflects better early recognition of Fragile X syndrome - once diagnosed, these children may not reach ASD clinics, creating selection bias in "unselected" cohorts 1.
Testing Method
Use DNA-based PCR methods to detect CGG repeat expansions in the FMR1 gene 3, 4, 5. Southern blot analysis can provide additional information about methylation status when needed 3.
Management of Positive Results
Full Mutation (>200 CGG repeats)
Males:
- All males with full mutations have Fragile X syndrome to some degree 3
- Severity cannot be predicted from mutation size alone 3
- Presence of premutations or unmethylated full mutations may indicate milder phenotype 3
Females:
- Wide phenotypic spectrum - can range from severe impairment to no detectable deficits 3
- Severity cannot be predicted from mutation size or X-inactivation pattern 3
- Approximately 20% of boys with Fragile X meet diagnostic criteria for ASD 1
Premutation (55-200 CGG repeats)
Critical counseling point: Premutation carriers should NOT be interpreted as unaffected 3
Risks to communicate:
- Females: Risk for fragile X-associated primary ovarian insufficiency (FXPOI) and fragile X-associated tremor/ataxia syndrome (FXTAS) 3
- Males: Risk for FXTAS 3
- If found in a patient referred for ASD/intellectual disability, consider it a coincidental finding unless FMRP deficiency or mosaicism is detected 3
Intermediate Alleles (45-54 CGG repeats)
Common Pitfalls to Avoid
Don't skip testing in high-functioning individuals: Fragile X can present with ASD without intellectual disability, particularly in females 2
Don't assume negative family history rules out testing: Many cases represent new mutations or unrecognized carriers in the family
Don't stop at premutation identification: If a premutation is found in someone with significant symptoms, investigate for FMRP deficiency or mosaicism 3
Don't order as standalone test: Fragile X testing should be part of a comprehensive genetic evaluation including chromosomal microarray 3, 1
Expected Overall Diagnostic Yield
A thorough clinical genetics evaluation (including CMA, Fragile X, MECP2, PTEN, and other targeted tests) identifies an etiology in 30-40% of individuals with ASD 1.